Reza Boostani - Department of Neurology, Mashhad University of Medical Sciences, Mashhad, Iran
Nasim Lotfinejad - Department of Research, Faculty of Medicine, Mashhad University of medical sciences, Mashhad, Iran
Fariba Zemorshidi - Department of Neurology, Mashhad University of Medical Sciences, Mashhad, Iran
Zohreh Vahidi - Immunology Research Centre, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran
Seyed Abdolrahim Rezaee - Immunology Research Centre, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran
Reza Farid - Allergy Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran
Houshang Rafatpanah - Immunology Research Centre, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran

Prevention and treatment of the Human T-cell leukemia virus, type ۱ (HTLV-۱) which was discovered nearly ۴۰ years ago, still remain challenging. The reported high prevalence of HTLV-۱ in some countries around the world triggered an open letter to the World Health Organization (WHO), urging action against HTLV-۱ infection in ۲۰۱۸. This highlights the importance of virus elimination strategies to eradicate HTLV-۱ infection. In Iran, we have documented our experiences with the virus in order to achieve and promote the possible ways to manage, control, and eliminate HTLV-۱. Although there has been considerable progress apropos of HTLV-۱, a series of additional challenges need to be tackled to control HTLV-۱ infection in Iran. 

ATL HAM/TSP HTLV, ۱ Prevention Treatments